X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20282) 20282
Book Review (2681) 2681
Publication (954) 954
Newsletter (194) 194
Book Chapter (34) 34
Conference Proceeding (26) 26
Magazine Article (19) 19
Dissertation (4) 4
Report (4) 4
Newspaper Article (3) 3
Web Resource (2) 2
Government Document (1) 1
Paper (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (18108) 18108
humans (17046) 17046
female (12805) 12805
male (9361) 9361
middle aged (9294) 9294
adult (8748) 8748
cyclophosphamide (8661) 8661
cyclophosphamide - administration & dosage (7343) 7343
oncology (6872) 6872
cyclophosphamide - adverse effects (6780) 6780
aged (6395) 6395
antineoplastic combined chemotherapy protocols - therapeutic use (6211) 6211
antineoplastic combined chemotherapy protocols - adverse effects (5376) 5376
chemotherapy (4796) 4796
cyclophosphamide - therapeutic use (4228) 4228
treatment outcome (4015) 4015
hematology (3491) 3491
cancer (3204) 3204
adolescent (3097) 3097
doxorubicin - administration & dosage (3070) 3070
breast neoplasms - drug therapy (2717) 2717
therapy (2697) 2697
vincristine - administration & dosage (2369) 2369
abridged index medicus (2316) 2316
animals (2251) 2251
antineoplastic combined chemotherapy protocols - administration & dosage (2209) 2209
child (2037) 2037
retrospective studies (1969) 1969
doxorubicin - adverse effects (1958) 1958
transplantation (1955) 1955
care and treatment (1925) 1925
combined modality therapy (1852) 1852
drug administration schedule (1816) 1816
prognosis (1780) 1780
rituximab (1770) 1770
drug therapy, combination (1721) 1721
disease-free survival (1654) 1654
follow-up studies (1642) 1642
prednisone - administration & dosage (1590) 1590
antineoplastic agents - adverse effects (1581) 1581
immunosuppressive agents - therapeutic use (1579) 1579
breast cancer (1542) 1542
vincristine - adverse effects (1542) 1542
time factors (1463) 1463
aged, 80 and over (1442) 1442
risk factors (1421) 1421
immunology (1415) 1415
doxorubicin (1399) 1399
medicine & public health (1381) 1381
survival analysis (1368) 1368
remission induction (1346) 1346
neoplasm staging (1341) 1341
etoposide - administration & dosage (1332) 1332
child, preschool (1328) 1328
survival rate (1283) 1283
methotrexate - administration & dosage (1281) 1281
dose-response relationship, drug (1272) 1272
research (1221) 1221
immunosuppressive agents - adverse effects (1209) 1209
mice (1199) 1199
survival (1192) 1192
prednisone - adverse effects (1170) 1170
prospective studies (1169) 1169
fluorouracil - administration & dosage (1156) 1156
young adult (1151) 1151
cisplatin - administration & dosage (1144) 1144
analysis (1143) 1143
trial (1128) 1128
health aspects (1117) 1117
toxicity (1085) 1085
antineoplastic agents - therapeutic use (1084) 1084
pharmacology & pharmacy (1080) 1080
breast neoplasms - pathology (1074) 1074
prednisone - therapeutic use (1024) 1024
drug therapy (1021) 1021
recurrence (1019) 1019
rheumatology (997) 997
vincristine - therapeutic use (995) 995
doxorubicin - therapeutic use (984) 984
methotrexate - adverse effects (964) 964
lymphoma, non-hodgkin - drug therapy (880) 880
clinical trials as topic (872) 872
medicine, general & internal (837) 837
non-hodgkins-lymphoma (833) 833
methotrexate (826) 826
lymphomas (820) 820
cisplatin (819) 819
children (806) 806
clinical trials (798) 798
antineoplastic agents - administration & dosage (797) 797
anthracyclines (791) 791
disease (788) 788
ovarian neoplasms - drug therapy (785) 785
chemotherapy, adjuvant (781) 781
patients (781) 781
leukemia (772) 772
bone-marrow-transplantation (771) 771
hematology, oncology and palliative medicine (768) 768
stem cells (759) 759
fluorouracil - adverse effects (749) 749
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18829) 18829
German (403) 403
Japanese (376) 376
French (228) 228
Russian (158) 158
Spanish (144) 144
Chinese (143) 143
Italian (58) 58
Polish (56) 56
Hungarian (21) 21
Portuguese (19) 19
Dutch (15) 15
Czech (14) 14
Danish (11) 11
Norwegian (11) 11
Slovak (7) 7
Korean (6) 6
Swedish (5) 5
Bulgarian (4) 4
Croatian (3) 3
Romanian (3) 3
Serbian (3) 3
Turkish (3) 3
Ukrainian (3) 3
Hebrew (2) 2
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Prospective Studies | Hodgkin Disease - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Positron-Emission Tomography | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Treatment Failure | Hodgkin Disease - drug therapy | Adult | Female | Radiotherapy Dosage | Etoposide - adverse effects | Prednisone - adverse effects | Proportional Hazards Models | Etoposide - therapeutic use | Treatment Outcome | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 1, pp. 13 - 21
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 32, pp. 3651 - 3658
Purpose The Children's Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of early chemotherapy response in... 
TRIAL | MORTALITY | ABVD | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | INVOLVED-FIELD RADIATION | PEDIATRIC-PATIENTS | DISEASE | FOLLOW-UP | CHILDHOOD-CANCER SURVIVOR | NO RADIOTHERAPY | Cyclophosphamide - administration & dosage | Hodgkin Disease - pathology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Hodgkin Disease - radiotherapy | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Female | Child | Infant, Newborn | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Bleomycin - administration & dosage | Bleomycin - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Cisplatin - adverse effects | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus | Pedi9 | ORIGINAL REPORTS | Hema14
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Summary Background Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide,... 
Hematology, Oncology and Palliative Medicine | THERAPY | OLDER PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | RANDOMIZED CONTROLLED-TRIAL | TARGETING BTK | ELDERLY-PATIENTS | CHEMOTHERAPY | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 19, pp. 2944 - 2952
This randomized, noninferiority (NI), global, phase 3 study evaluated the efficacy and safety of bendamustine plus rituximab(BR) vs a standard... 
REFRACTORY INDOLENT | THERAPY | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | CHRONIC LYMPHOCYTIC-LEUKEMIA | PHASE-II MULTICENTER | HEMATOLOGY | Cyclophosphamide - administration & dosage | Peripheral Nervous System Diseases - chemically induced | Nausea - chemically induced | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fatigue - chemically induced | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Paresthesia - chemically induced | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Prednisone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Vomiting - chemically induced | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Alopecia - chemically induced | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Index Medicus | Abridged Index Medicus | 8 | Clinical Trials and Observations | 39 | 29
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 10/2012, Volume 23, Issue 9, pp. 991 - 995
Journal Article